Brief: Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
02/06/2025 13:10
June 2 (Reuters) - GSK plc GSK.L: THERAVANCE BIOPHARMA, INC. SELLS REMAINING ROYALTY INTEREST IN TRELEGY ELLIPTA TO GSK FOR $225 MILLION THERAVANCE BIOPHARMA INC - FINANCIAL GUIDANCE FOR 2025 REMAINS UNCHANGED THERAVANCE BIOPHARMA INC - RETAINS RIGHTS TO UP TO $150 MILLION IN MILESTONES FROM ROYALTY PHARMA ON TRELEGY ELLIPTA NET SALES IN 2025 & 2026 Source text: ID:nPnbyNcpNa Further company coverage: GSK.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsTheravance Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
Brief: Theravance Biopharma Q2 Operating Income USD -8.277 Million
Press Digest: Canada - June 30
Deals of the day-Mergers and acquisitions